U.S. Life Sciences Stock News

Vaxcyte (NasdaqGS:PCVX) has launched a comprehensive Phase 3 adult clinical program for its VAX-31 pneumococcal conjugate vaccine. The company has completed enrollment in a Phase 2 study of VAX-31 in infants. Vaxcyte is preparing to advance a separate vaccine candidate targeting Group A Streptococcus. These moves follow FDA alignment and an expanded Breakthrough Therapy designation for VAX-31. Vaxcyte, trading at about $61.35, is moving into a more mature stage of its pipeline, with VAX-31...

Oncolytics Biotech (ONCY) has attracted fresh attention after a recent move in its share price, with the stock closing at US$1.13 and showing mixed return patterns across the past year and over multiple years. See our latest analysis for Oncolytics Biotech. The recent 6.6% 1 day share price return and 10.8% 7 day share price return suggest short term momentum is building around Oncolytics Biotech, even as the 58.3% 1 year total shareholder return contrasts with weaker 3 and 5 year total...

Preferred Bank reclassified a sizable loan relationship from substandard to nonaccrual status following ongoing legal complications involving the borrower’s principals. The borrower is facing complex lawsuits that have contributed to cash flow pressures and payment issues on the loan. Management has indicated that, based on current expectations, the ultimate resolution of this credit is not expected to significantly affect 2026 earnings. For you as an investor following NasdaqGS:PFBC, this...

The Morning Bull - US Market Morning Update Wednesday, Feb, 25 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.1% and Nasdaq-100 futures ahead by roughly 0.2%, as investors weigh stronger hiring against easier borrowing costs. Fresh figures from ADP show private employers adding around 12,750 jobs a week over the past month, the fastest pace since late November, which signals companies are still hiring and paychecks are still flowing...

If you are trying to work out whether OneStream is attractively priced or not, this article will walk through what its current valuation might be telling you. With the share price at US$23.48 and returns of 0.4% over 7 days, a 0.6% decline over 30 days and 32.5% year to date, OneStream has caught the eye of investors who are watching how sentiment could be shifting. Recent coverage has focused on OneStream as part of the broader conversation around software names, which helps explain why...

FDA milestones put Larimar Therapeutics (LRMR) and nomlabofusp in sharper focus Larimar Therapeutics (LRMR) is back on investors’ radar after the FDA granted Breakthrough Therapy Designation to its Friedreich's ataxia candidate nomlabofusp and signaled openness to a surrogate endpoint supporting a potential accelerated approval filing. See our latest analysis for Larimar Therapeutics. The FDA update has arrived alongside a sharp pickup in momentum, with a 1 day share price return of 31.32%...

In February 2026, Clean Energy Fuels reported fourth-quarter 2025 results showing revenue of US$112.32 million and a wider net loss of US$43.00 million, alongside guidance for a 2026 net loss attributable to the company of US$71.00 million to US$66.00 million, excluding unrealized contract impacts and estimated US$47.00 million of Amazon warrant charges. The company also flagged that swings in diesel and natural gas markets, plus variations in Amazon warrant vesting, could materially alter...

Lindsay (NYSE:LNN) has introduced two new safety products, the Road Runner Truck-Mounted Attenuator and the AlphaGuard Channelizing Device. The products expand the company’s roadway and work zone safety lineup, targeting construction and traffic management applications. Both launches focus on work zone protection, operational efficiency, and evolving infrastructure management needs. Lindsay, trading at $135.74, is building on its position in roadway and infrastructure safety with these new...

If you are wondering whether PicS is attractively priced at its recent levels, this article will walk through what the current numbers are really saying about the stock. The share price recently closed at US$16.81, with a 7 day return of 27.4% and a year to date return of an 11.5% decline. This has caught the attention of investors who are considering the balance between growth potential and risk. Recent news coverage around PicS has focused on its positioning within the diversified...

Pamela Seymon and former CEO Sharmistha Dubey plan to leave Match Group's Board at the 2026 Annual Meeting. The departures will change the board composition at NasdaqGS:MTCH and affect its governance structure. Investors are watching for how these board changes may influence oversight and long term company direction. Match Group, the parent of several online dating platforms, sits at the center of how people form relationships through digital services. As user behavior, regulation, and...

Select Medical Holdings (NYSE:SEM) has received a nonbinding indication of interest to take the company private. A special committee of the Board is currently reviewing the proposal. The approach represents a potential change in ownership structure and corporate control. For shareholders, the timing of this approach comes after a mixed share price record. The stock closed at $14.82, with a 1-year return of a 21.3% decline and a 3-year return of a 6.6% decline. Over 5 years, the share price...

Harmonic has agreed to sell its Video business to MediaKind, repositioning itself as a pure-play broadband company. The company is integrating its broadband technology with ATX Networks to support cable operators upgrading their networks. A multi-year agreement with izzi in Mexico targets large scale fiber expansion using Harmonic solutions. Harmonic, ticker NasdaqGS:HLIT, is refocusing around broadband at a time when its shares trade at $10.44. The stock shows mixed longer term...

Empire State Realty Trust reported fourth-quarter 2025 results with higher revenue and net income, renewed and expanded major Manhattan leases with tenants including Burlington, TJ Maxx, JP Morgan Chase, and Nespresso, and completed a US$6,000,000 share repurchase program that retired 891,530 shares. In February 2026, the company reinforced its income profile with first-quarter 2026 common and preferred dividends and highlighted a fully New York City-focused portfolio and award-winning...

Why Camping World Holdings Stock Is Drawing Attention Now Camping World Holdings (CWH) has been on investors’ radar after a stretch of weaker share performance, including a 1-month return of 24.6% and a past 3 months return of 4.2%. At a last close of US$10.85, the company combines annual revenue of about US$6.4b with a reported net income loss of US$54.1 million, giving investors a mix of scale and current profitability questions to weigh. See our latest analysis for Camping World...

Full year 2025 results (Adjusted / non-GAAP): Adjusted EPS: US$0.37 (vs consensus US$0.31, a 19.35% beat). Adjusted earnings: US$21.56m (vs consensus US$18.04m, a 19.54% beat). Adjusted EPS increased from US$0.17 in FY 2024.

Avidity Biosciences (RNA) has wrapped up FY 2025 with fourth quarter revenue of about US$0.9 million, a basic EPS loss of US$1.54 and a net loss of roughly US$237.1 million. Over recent quarters the company has seen revenue move from US$2.3 million in Q3 2024 to US$12.5 million in Q3 2025. Basic EPS shifted from a loss of US$0.65 in Q3 2024 to a loss of US$1.27 in Q3 2025, and trailing 12 month EPS landed at a loss of US$4.97. This sets the stage for a results season where investors are...

Targa Resources (NYSE:TRGP) announced a major build out of natural gas processing plants in the Permian Basin. The company is adding a new large scale NGL fractionator, Train 13, at its Mont Belvieu complex. Targa outlined additional growth projects, including carbon capture initiatives and AI driven technology upgrades across its system. The expansion is described as aimed at meeting rising energy demand tied to data centers and broader market needs. Targa Resources, a large midstream...

Cogent Biosciences (NasdaqGS:COGT) has advanced its lead therapy bezuclastinib into a Phase 3 trial for systemic mastocytosis. The company has also filed a significant shelf registration that could be used to raise capital in the future. These updates highlight progress in Cogent Biosciences' clinical pipeline alongside preparations for potential funding needs. Cogent Biosciences enters this news cycle with its shares at $39.18 and very large 1 year returns, reflecting strong recent...

Great Lakes Dredge & Dock (GLDD) capped FY 2025 with Q4 revenue of US$256.5 million and basic EPS of US$0.19, rounding out a trailing twelve month picture that includes total revenue of US$888.3 million and EPS of US$1.10. Over the past few quarters, the company has seen revenue move from US$191.2 million in Q3 2024 to US$202.8 million in Q4 2024, then to US$242.9 million in Q1 2025 and US$195.2 million in Q3 2025, with quarterly EPS ranging from US$0.13 to US$0.50 over the same stretch. This...

Clearway Energy (CWEN.A) just closed out FY 2025 with Q4 revenue of US$310 million and a basic EPS loss of US$0.85, capping a trailing twelve month period that totaled US$1.4 billion of revenue and US$1.42 in basic EPS. The company has seen quarterly revenue move from US$256 million in Q4 2024 to US$310 million in Q4 2025. Over the same period, basic EPS shifted from US$0.03 to a loss of US$0.85, against a backdrop of trailing twelve month net income of US$169 million. For investors, that mix...

THOR Industries (NYSE:THO) has reorganized its North American RV operations to create two new operating groups focused on alignment and efficiency. The company announced related executive leadership changes as part of this restructuring. The move is intended to reshape how THOR coordinates its brands and manages its RV segment across North America. THOR Industries, a major manufacturer in the recreational vehicle space, sits at the center of a sector that is closely tied to consumer...

Why Gossamer Bio’s PROSERA readout matters now Gossamer Bio (GOSS) has drawn fresh attention after releasing topline Phase 3 PROSERA data for seralutinib in pulmonary arterial hypertension and scheduling a special call to review the results and potential next steps with regulators. See our latest analysis for Gossamer Bio. The unveiling of the PROSERA Phase 3 topline data and the planned FDA discussions come after a sharp reset in sentiment, with a 30 day share price return of 84.32% decline...

If you are wondering whether OFG Bancorp at around US$41.39 is still good value or already pricing in a lot of optimism, you are asking the right question. The stock has had mixed recent returns, with a 1.2% decline over the last 7 days, an 11.4% gain over 30 days, 0.9% year to date, 2.4% over 1 year, 50.3% over 3 years and 134.3% over 5 years, which can change how investors think about both upside and risk. Recent news around OFG Bancorp has focused on its position as a US regional bank and...

Ategrity Specialty Insurance Company Holdings (ASIC) has drawn fresh attention after a sharp recent move in its share price, with the stock up 6.1% over the past day and 32.7% in the past week. See our latest analysis for Ategrity Specialty Insurance Company Holdings. The recent surge in Ategrity Specialty Insurance Company Holdings’ share price, including a 32.7% 7 day share price return and a 23.97% 90 day share price return, suggests short term momentum is building while year to date...